Prospective Study Evaluating Postoperative Radiotherapy Plus 2-Year Androgen Suppression for Post-Radical Prostatectomy Patients With Pathologic T3 Disease and/or Positive Surgical Margins

International Journal of Radiation Oncology Biology Physics

Volumn 75, Issue 2, 2009, Pages 407-412

  Choo, Richard ^a   Danjoux, Cyril ^b   Gardner, Sandra ^b   Morton, Gerard ^b   Szumacher, Ewa ^b   Loblaw, D Andrew ^b   Cheung, Patrick ^b   Pearse, Maria ^c  

^a MAYO CLINIC   (United States)

^b DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^c AUCKLAND CITY HOSPITAL   (New Zealand)

Author keywords

Pathologic T3 and or positive resection margin; Postoperative radiotherapy plus androgen suppression; Prostate cancer

Indexed keywords

ANDROGEN SUPPRESSION; COMBINED TREATMENT; COX REGRESSION ANALYSIS; KAPLAN-MEIER METHOD; PATHOLOGIC T3 AND/OR POSITIVE RESECTION MARGIN; POSITIVE SURGICAL MARGIN; POSTOPERATIVE RADIOTHERAPY; POSTOPERATIVE RADIOTHERAPY PLUS ANDROGEN SUPPRESSION; PROGNOSTIC FACTORS; PROSPECTIVE STUDY; PROSTATE CANCER; PROSTATE SPECIFIC ANTIGEN; RADICAL PROSTATECTOMY; SURVIVAL RATE;

ANTIGENS; PULSE MODULATION; RADIOTHERAPY; REGRESSION ANALYSIS;

PEELING;

BUSERELIN ACETATE; NILUTAMIDE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; GLEASON SCORE; GROUPS BY AGE; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MORBIDITY; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROSTATE ADENOCARCINOMA; PROSTATECTOMY; RADIATION DOSE; TUMOR RECURRENCE;

AGED; ANDROGEN ANTAGONISTS; BUSERELIN; COMBINED MODALITY THERAPY; HUMANS; IMIDAZOLIDINES; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEOPLASM, RESIDUAL; PILOT PROJECTS; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; REGRESSION ANALYSIS; SURVIVAL RATE;

EID: 69549135458     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2008.11.007     Document Type: Article

References (13)

1. Bolla M., van Poppel H., Collette L., et al. Postoperative radiotherapy after radical prostatectomy: A randomised controlled trial (EORTC trial 22911). Lancet 366 (2005) 572-578
2. Thompson Jr. I.M., Tangen C.M., Paradelo J., et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: A randomized clinical trial. JAMA 296 (2006) 2329-2335
3. Wiegel T., Bottke D., Willich N., et al. Phase III results of adjuvant radiotherapy (RT) versus "wait and see" (WS) in patients with pT3 prostate cancer following radical prostatectomy (RP) (ARO 96-02 / AUO AP 09/95) (Abstr.). J Clin Oncol 23 Suppl. 16S (2005) 381s
4. Choo R., Pearce A., Danjoux C., et al. Prospective evaluation of quality of life in prostate cancer patients receiving combined treatment of postoperative radiotherapy plus androgen suppression for PT3 and/or positive resection margin following radical prostatectomy. Eur Urol 52 (2007) 1645-1652
5. Choo R., Pearse M., Danjoux C., et al. Analysis of gastrointestinal and genitourinary morbidity of postoperative radiotherapy for pathologicT3 or positive surgical margins after radical prostatectomy using the NCI Expanded Common Toxicity Criteria. Int J Radiat Oncol Biol Phys 72 (2008) 989-995
6. Kaplan E.L., and Meier P. Nonparametric estimation from incomplete observations. Am Stat Assoc J 53 (1958) 457-481
7. Cox D.R. Regression models and life tables. J R Stat Soc B34 (1972) 187-220
8. Anscher M.S., Robertson C.N., and Prosnitz R. Adjuvant radiotherapy for pathologic stage T3/4 adenocarcinoma of the prostate: Ten-year update. Int J Radiat Oncol Biol Phys 33 (1995) 37-43
9. Valicenti R.K., Gomella L.G., Ismail M., et al. The efficacy of early adjuvant radiation therapy for pT3N0 prostate cancer: A matched-pair analysis. Int J Radiat Oncol Biol Phys 45 (1999) 53-58
10. Leibovich B.C., Engen D.E., Patterson D.E., et al. Benefit of adjuvant radiation therapy for localized prostate cancer with a positive surgical margin. J Urol 163 (2000) 1178-1182
11. Choo R., Hruby G., Hong J., et al. Positive resection margin and/or pathologic T3 adenocarcinoma of prostate with undetectable postoperative prostate-specific antigen after radical prostatectomy: To irradiate or not?. Int J Radiat Oncol Biol Phys 52 (2002) 674-680
12. Taylor N., Kelly J.F., Kuban D.A., et al. Adjuvant and salvage radiotherapy after radical prostatectomy for prostate cancer. Int J Radiat Oncol Biol Phys 56 (2003) 755-763
13. Vargas C., Kestin L.L., Weed D.W., et al. Improved biochemical outcome with adjuvant radiotherapy after radical prostatectomy for prostate cancer with poor pathologic features. Int J Radiat Oncol Biol Phys 61 (2005) 714-724